Landec Corporation (LNDC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Landec Corporation (LNDC) Healthcare & Pipeline Overview

Landec Corporation (LNDC) develops and markets health and wellness products, operating through Lifecore, which manufactures pharmaceutical-grade sodium hyaluronate, and Curation Foods, which focuses on olive oils, vinegars, and avocado products. The company serves both medical and consumer markets internationally.

What Is the Investment Thesis for LNDC?

Landec Corporation presents a mixed investment profile. With a market capitalization of $264M and a negative profit margin of -25.2%, the company faces profitability challenges. However, its gross margin of 31.2% indicates potential in its core operations. The Lifecore segment, with its focus on pharmaceutical-grade sodium hyaluronate, offers growth opportunities in the medical sector. The Curation Foods segment provides diversification, although it operates in a competitive consumer market. Key catalysts include potential partnerships within the Lifecore segment and successful product launches in the Curation Foods segment. Ongoing risks include the company's negative profit margin and the competitive pressures in both the pharmaceutical and food markets. Investors should closely monitor Landec's ability to improve profitability and capitalize on its market opportunities.

Based on FMP financials and quantitative analysis

LNDC Key Highlights

Market Cap of $264M reflects its current valuation in the market.

• Gross Margin of 31.2% indicates the profitability of its products before operating expenses.
• Profit Margin of -25.2% highlights ongoing challenges in achieving overall profitability.
• Beta of 1.10 suggests that the stock is slightly more volatile than the market.
• No Dividend Yield reflects the company's current focus on reinvesting earnings for growth.

Who Are LNDC's Competitors?

LNDC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LNDC's Key Strengths?

Established presence in the pharmaceutical-grade sodium hyaluronate market.

• Recognized brands in the avocado food market.
• Diversified revenue streams through Lifecore and Curation Foods segments.
• Strong relationships with pharmaceutical partners.

What Are LNDC's Weaknesses?

Negative profit margin indicates profitability challenges.

• Exposure to commodity price fluctuations in the food segment.
• Dependence on key suppliers for raw materials.
• Limited geographic diversification.

What Could Drive LNDC Stock Higher?

Potential FDA approval for new HA-based injectable products in the Lifecore segment.

• Strategic partnerships with pharmaceutical companies to co-develop and commercialize HA-based products.
• Expansion of Curation Foods' distribution network in North America.
• Product innovation in the avocado food market, with new product launches planned for 2027.

What Are the Key Risks for LNDC?

Financial-distress signal — its Altman Z-Score of 0.05 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition in the pharmaceutical and food markets.
• Stringent regulatory requirements for pharmaceutical products.
• Fluctuations in avocado prices affecting Curation Foods' profitability.
• Economic downturns affecting consumer spending on food products.
• Negative profit margin indicating ongoing profitability challenges.

What Are the Growth Opportunities for LNDC?

• Expansion of Lifecore's HA Product Line: Lifecore has the opportunity to expand its pharmaceutical-grade sodium hyaluronate (HA) product line into new therapeutic areas, such as dermatology and wound care. The global HA market is projected to reach $11.9 billion by 2028, growing at a CAGR of 8.2%. By developing new HA-based products and formulations, Lifecore can tap into this growing market and increase its revenue streams. Timeline: 2-3 years for product development and regulatory approvals.
• Strategic Partnerships in the Pharmaceutical Sector: Lifecore can pursue strategic partnerships with pharmaceutical companies to co-develop and commercialize HA-based injectable products. These partnerships can provide Lifecore with access to new markets, technologies, and funding. The pharmaceutical industry is increasingly relying on collaborations to drive innovation and reduce risk. By partnering with established players, Lifecore can accelerate its growth and expand its market reach. Timeline: Ongoing.
• Geographic Expansion of Curation Foods: Curation Foods has the potential to expand its geographic footprint by entering new markets in North America and internationally. The market for fresh avocado products is growing rapidly, driven by increasing consumer demand for healthy and convenient foods. By expanding its distribution network and marketing efforts, Curation Foods can increase its sales and market share. Timeline: 1-2 years for market entry and distribution setup.
• Product Innovation in Curation Foods: Curation Foods can drive growth by introducing new and innovative avocado-based products, such as flavored guacamole, avocado dips, and ready-to-eat avocado snacks. The market for innovative food products is constantly evolving, and consumers are always looking for new and exciting options. By investing in research and development, Curation Foods can stay ahead of the curve and capture new market opportunities. Timeline: Ongoing.
• Vertical Integration of Avocado Supply Chain: Curation Foods can improve its profitability and supply chain resilience by vertically integrating its avocado supply chain. This can involve acquiring avocado farms, processing facilities, and distribution networks. By controlling its supply chain, Curation Foods can reduce its costs, improve its product quality, and ensure a reliable supply of avocados. Timeline: 3-5 years for full integration.

What Are LNDC's Competitive Advantages?

• Proprietary technology in the production of pharmaceutical-grade sodium hyaluronate.
• Established relationships with pharmaceutical companies in the Lifecore segment.
• Brand recognition for the Yucatan and Cabo Fresh brands in the avocado food market.
• Vertically integrated supply chain for avocado products.

What Does LNDC Do?

Landec Corporation, established in 1986 and headquartered in Santa Maria, California, operates as a diversified health and wellness company. It designs, develops, manufactures, and sells differentiated products across the food and biomaterials markets, both in the United States and internationally. The company is structured into three primary segments: Lifecore, Curation Foods, and Other. The Lifecore segment is dedicated to the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products. These products are utilized in treating a range of medical conditions and procedures. Lifecore also provides technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies, serving partners with both HA-based and non-HA based aseptically formulated and filled products. The non-HA products are primarily sold for medical use in the ophthalmic, orthopedic, and other markets. The Curation Foods segment focuses on processing, marketing, and selling olive oils and wine vinegars under the O brand, as well as guacamole and avocado food products under the Yucatan and Cabo Fresh brands. Additionally, Curation Foods engages in various private label arrangements. Landec's evolution reflects a strategic diversification into health and wellness markets, leveraging its technological and manufacturing capabilities to serve both the medical and consumer sectors.

What Products and Services Does LNDC Offer?

• Designs, develops, and manufactures health and wellness products.
• Produces pharmaceutical-grade sodium hyaluronate (HA) for medical applications.
• Offers HA in bulk form, as well as formulated and filled syringes and vials.
• Provides services for technology and formulation development.
• Processes, markets, and sells olive oils and wine vinegars under the O brand.
• Produces and sells guacamole and avocado food products under the Yucatan and Cabo Fresh brands.
• Engages in private label arrangements for food products.

How Does LNDC Make Money?

• Lifecore segment generates revenue through the sale of HA and related services to pharmaceutical companies.
• Curation Foods segment generates revenue through the sale of olive oils, vinegars, guacamole, and avocado products to retailers and consumers.
• The company also generates revenue through private label arrangements.

What Industry Does LNDC Operate In?

Landec Corporation operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market for pharmaceutical-grade sodium hyaluronate, a key product of Landec's Lifecore segment, is driven by the increasing demand for injectable products in ophthalmology, orthopedics, and other medical fields. The Curation Foods segment operates in the competitive food processing industry, where consumer preferences and supply chain efficiencies are critical. Landec's success depends on its ability to differentiate its products, manage costs, and navigate the evolving regulatory landscape.

Who Are LNDC's Key Customers?

• Pharmaceutical companies that use HA in their injectable products.
• Retailers that sell olive oils, vinegars, guacamole, and avocado products.
• Consumers who purchase the company's food products under the O, Yucatan, and Cabo Fresh brands.
• Private label customers who contract with Curation Foods to produce food products under their own brands.

Key Financial Metrics

Return on assets is -16.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.0%, the inverse of the P/E and a quick read on earnings relative to price.

Landec Corporation (LNDC) Valuation Context

Valued at $264M, LNDC is classified as a micro-cap stock. Relative to its peer group, LNDC's quantitative score of 45/100 is below the peer average of 62/100.

Company Profile

Landec Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Albert Bolles. LNDC has traded publicly since 1996.

Landec Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.05 places it in the distress zone, a signal of elevated financial risk.

LNDC Financials

LNDC Latest News

No recent news available for LNDC.

LNDC Analyst Consensus

LNDC MoonshotScore

Landec Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources